Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment

CNS Spectrums

Volumn 2, Issue 8, 1997, Pages 41-55

  Harvey, Philip D ^a   Keefe, Richard S E ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001844256     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900005034     Document Type: Review

References (68)

1. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, Scotland: E. & S. Livingstone; 1919.
2. Hunt JM, Cofer C. Psychological deficit. In: Hunt JM, ed. Personality and Behavior. New York, NY: Ronald Press; 1944;971-1032.
3. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618-623.
4. Perlick D, Stastny P, Mattis S, Teresi J. Contribution of family, cognitive, and clinical dimensions to long-term outcome in schizophrenia. Schizophr Res. 1992;6:257-265.
5. Young DA, Davila R, Scher H. Unawareness of illness and neuropsychological performance in schizophrenia. Schizophr Res. 1993;10:117-124.
6. Amador XF, Strauss DH, Yale SA, et al. Awareness of illness in schizophrenia. Schizophr Bull. 1991;17:113-132.
7. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 1988;3:249-271.
8. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:478-486.
9. Walker E, Green MF. Motor proficiency and attention-task performance by schizophrenic patients. J Abnorm Psychol. 1982;91:261-268.
10. Earle-Boyer EA, Serper MR, Davidson M, et al. Auditory and visual continuous performance tests in medicated and unmedicated schizophrenic patients: clinical and motoric correlates. Psychiatry Res. 1991;37:47-56.
11. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res. 1990;3:127-129.
12. Davidson M, Harvey PD, Powchik P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995;152:197-207.
13. Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. 1991;4:123-134.
14. Putnam KM, Harvey PD, Parrella M, et al. Symptom stability in geriatric chronic schizophrenic inpatients: a one-year follow-up study. Biol Psychiatry. 1996;39:92-99.
15. Harvey PD, Lombardi J, Leibman M, et al. Cognitive impairment and negative symptoms in schizophrenia: a prospective study of their relationship. Schizophr Res. 1996;22:223-231.
16. Leff JP, Thornicroft G, Coxhead N, et al. The TAPS Project. 22: a five-year follow-up of long stay psychiatric patients discharged to the community. Br J Psychiatry. 1994;165:(suppl 25):13-17.
17. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
18. Hoffman RE, Stopek S, Andreasen NC. A discourse analysis comparing manic versus schizophrenic speech disorganization. Arch Gen Psychiatry. 1986;43:831-838.
19. Harvey PD. Speech competence in manic and schizophrenic psychoses: the association between clinically rated thought disorder and cohesion and reference performance. J Abnorm Psychol. 1983;92:368-377.
20. Spitzer M. The psychopathology, neuropsychology, and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1993;243:57-70.
21. Goldberg TE, Gold JM, Greenberg R, et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry. 1993;150:1355-1362.
22. Knight RA, Roff JD, Barrnet J, et al. Concurrent and predictive validity of thought disorder and affectivity: a 22 year followup of acute schizophrenics. J Abnorm Psychol. 1979;88:1-12.
23. Keefe RS, Mohs RC, Losonczy MF, et al. Characteristics of very poor outcome schizophrenia. Am J Psychiatry. 1987;144:889-895.
24. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239-246.
25. Harvey PD, Davidson M, Mueser K, et al. The Social Adaptive Functioning Evaluation: an assessment measure for geriatric psychiatric patients. Schizophr Bull. 1997;23:131-146.
26. Heaton RK, Drexler M. Clinical neuropsychological findings in schizophrenia and aging. In: Miller NE, Cohen GD, eds. Schizophrenia and Aging. New York, NY: Gulford Press; 1987:145-161.
27. Bergman A, Harvey PD, Mitroupolou V, et al. Learning and memory in patients with schizotypal personality disorder. Schizophr Bull. In press.
28. Harvey PD, Mohs RC, Keefe RSE, et al. Information processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Res. 1996;60:49-56.
29. Voglmaier MM, Seidman LJ, Salisbury D, et al. Neuropsychological dysfunction in schizotypal personality disorder: a profile analysis. Biol Psychiatry. 1997;41:530-540.
30. Oltmanns TF, Ohayon J, Neale JM. The effect of medication and diagnostic criteria on distractibility in schizophrenia. J Psychiatr Res. 1979;14:81-91.
31. Harvey PD, Pedley M. Auditory and visual distractibility in schizophrenics: clinical and medication status correlations. Schizophr Res. 1989;2:295-300.
32. Marder SR, Asarnow RF,. van Putten T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res. 1984;13:41-49.
33. Serper MR, Davidson M, Harvey PD. Attentional predictors of clinical change during neuroleptic treatment. Schizophr Res. 1994;13:65-71.
34. Asarnow RF, Marder SR, Mintz J, et al. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good and poor information-processing abilities. Arch Gen Psychiatry. 1988;45:822-826.
35. Harvey PD, Docherty NM, Serper MR, et al. Cognitive deficits and thought disorder: II. An eight-month followup study. Schizophr Bull. 1990;16:147-156.
36. Asarnow RF, MacCrimmon DJ. Residual performance deficit in clinically remitted schizophrenics: a marker of schizophrenia? J Abnorm Psychol. 1978;87:597-608.
37. Harvey PD, Winters KC, Weintraub S, et al. Distractibility in children vulnerable to psychopathology. J Abnorm Psychol. 1981;90:298-304.
38. Serper MR, Bergman RL, Harvey PD. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res. 1990;32:281-288.
39. Granholm E, Asarnow RF, Marder SR. Controlled information resources and the development of automatic detection responses in schizophrenia. J Abnorm Psychol. 1991;100:22-30.
40. Granholm E, Asarnow RF, Marder SR. Dual task performance operating characteristics, resource limitations, and automatic processing in schizophrenia. Neuropsychology. 1996;10:3-11.
41. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416.
42. Cooper LE, Kendell RE, Gurland BJ, et al. Psychiatric Diagnosis in New York and London, London, England: Oxford University Press; 1972.
43. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
44. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23:3-10.
45. Carpenter WT Jr. The risk of medication-free research. Schizophr Bull. 1997;23:11-18.
46. Loebel MD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992;149:1183-1189.
47. Bilder RM. Lipshitz-Broch L, Reiter G, et al. Intellectual deficits in first episode schizophrenia: evidence for progressive deterioration. Schizophr Bull. 1992;18:437-448.
48. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive first episode patients with schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.
49. Kaplan HI, Sadock BJ. Synposis of Psychiatry. 6th ed. Baltimore, Md: Williams and Wilkins; 1991.
50. Mortimer JA, Ebbitt B, Jun AP, et al. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42:1689-1696.
51. Green CR, Mobs RC, Schmeidler J, et al. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc. 1993;41:654-661.
52. Teri L, Borson S, Kiyak A, et al. Behavioral disturbance, cognitive dysfunction and functional skill: prevalence in relationship in Alzheimer's disease. J Am Geriatr Soc. 1989;37:109-116.
53. Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer's Disease with and without delusions. Am J Psychiatry. 1992;149:184-189.
54. Mohs RC. Neuropsychological assessment of patients with Alzheimer's Disease. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1377-1388.
55. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55:82-87.
56. Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996;6(suppl):S2-13-S2-20.
57. Berridge CW, Arnsten AF, Foote SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical, electrophysiological, and behavioural studies in animal models. Psychol Med. 1993;23:557-564.
58. Almaric M, Koob GF. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine systems. Prog Brain Res. 1993;99:209-226.
59. Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997;54:159-168.
60. Sahakian BJ, Coull JT. Tetrahydroaminoacridine (THA) in Alzheimer's Disease: an assessment of altentional and mnemonic function using CANTAB. Acta Neurol Scand. 1993;88:29-35.
61. Serper MR, Harvey PD. Attentional predictors of clinical change: II. Continuous Performance Test predictors of the rale of clinical change. Cognitive Neuropsychiatry. In press.
62. McGlashan TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull. 1988;14:515-542.
63. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms of idiopathic and drug-induced psychosis. Schizophr Bull. 1990;16:97-110.
64. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Deisler SH, Szymanski SR. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992;149:1183-1188.
65. Wyatt RJ. Early intervention for schizophrenia: can the course of illness be altered? Biol Psychiatry. 1995;38:1-3.
66. Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(suppl): 13S-21S.
67. Carpenter WT Jr. Serotonin-dopamine agonists and the treatment of negative symptoms. J Clin Psychopharmacol. 1995;15(suppl 1):30S-35S.
68. Van Putten T, Marder SR, Mintz J. A controlled dose study of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990;47:754-758.